Alterations in the BTB affect its permeability, and this structure participates in reciprocal regulatory pathways with tumour cells. Importantly, the BTB typically retains a heterogeneous capacity to restrict the penetration of many therapeutic agents into intracranial tumours, and overcoming this challenge is a key to improving the effectiveness of treatment and patient quality of life. Herein, current knowledge of BTB structure and function is reviewed from a cell and cancer biology standpoint, with a focus on findings derived from in vivo models and human tumour specimens.
The blood-tumour barrier in cancer biology and therapy
Patricia S Steeg 1Affiliations expand
- PMID: 34253912
- DOI: 10.1038/s41571-021-00529-6
Abstract
The protective blood-brain barrier has a major role in ensuring normal brain function by severely limiting and tightly controlling the ingress of substances into the brain from the circulation. In primary brain tumours, such as glioblastomas, as well as in brain metastases from cancers in other organs, including lung and breast cancers and melanoma, the blood-brain barrier is modified and is referred to as the blood-tumour barrier (BTB). Alterations in the BTB affect its permeability, and this structure participates in reciprocal regulatory pathways with tumour cells. Importantly, the BTB typically retains a heterogeneous capacity to restrict the penetration of many therapeutic agents into intracranial tumours, and overcoming this challenge is a key to improving the effectiveness of treatment and patient quality of life. Herein, current knowledge of BTB structure and function is reviewed from a cell and cancer biology standpoint, with a focus on findings derived from in vivo models and human tumour specimens. Additionally, how this knowledge can be translated into clinical advances for patients with cancer is discussed.
© 2021. This is a U.S. government work and not under copyright protection in the U.S.; foreign copyright protection may apply.
Similar articles
- The blood-brain barrier and blood-tumour barrier in brain tumours and metastases.Arvanitis CD, Ferraro GB, Jain RK.Nat Rev Cancer. 2020 Jan;20(1):26-41. doi: 10.1038/s41568-019-0205-x. Epub 2019 Oct 10.PMID: 31601988 Free PMC article. Review.
- PSMA-targeted nanoparticles for specific penetration of blood-brain tumor barrier and combined therapy of brain metastases.Ni J, Miao T, Su M, Khan NU, Ju X, Chen H, Liu F, Han L.J Control Release. 2021 Jan 10;329:934-947. doi: 10.1016/j.jconrel.2020.10.023. Epub 2020 Oct 16.PMID: 33069744
- Heterogeneity and vascular permeability of breast cancer brain metastases.Babak MV, Zalutsky MR, Balyasnikova IV.Cancer Lett. 2020 Oct 1;489:174-181. doi: 10.1016/j.canlet.2020.06.012. Epub 2020 Jun 16.PMID: 32561415
- Alterations in Pericyte Subpopulations Are Associated with Elevated Blood-Tumor Barrier Permeability in Experimental Brain Metastasis of Breast Cancer.Lyle LT, Lockman PR, Adkins CE, Mohammad AS, Sechrest E, Hua E, Palmieri D, Liewehr DJ, Steinberg SM, Kloc W, Izycka-Swieszewska E, Duchnowska R, Nayyar N, Brastianos PK, Steeg PS, Gril B.Clin Cancer Res. 2016 Nov 1;22(21):5287-5299. doi: 10.1158/1078-0432.CCR-15-1836. Epub 2016 May 31.PMID: 27245829 Free PMC article.
- Targeting Brain Tumors with Nanomedicines: Overcoming Blood Brain Barrier Challenges.Khaitan D, Reddy PL, Ningaraj N.Curr Clin Pharmacol. 2018;13(2):110-119. doi: 10.2174/1574884713666180412150153.PMID: 29651960 Review.
